CenterBook Partners LP Takes $2.55 Million Position in Lantheus Holdings, Inc. $LNTH

CenterBook Partners LP bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 38,354 shares of the medical equipment provider’s stock, valued at approximately $2,552,000. CenterBook Partners LP owned about 0.06% of Lantheus at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. M&T Bank Corp purchased a new position in Lantheus in the 4th quarter worth about $370,950,000. Norges Bank bought a new stake in shares of Lantheus in the fourth quarter worth approximately $76,197,000. Hotchkis & Wiley Capital Management LLC purchased a new position in shares of Lantheus during the third quarter valued at approximately $11,443,000. Reinhart Partners LLC. lifted its position in Lantheus by 15.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after purchasing an additional 214,820 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Lantheus by 73.4% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,452 shares of the medical equipment provider’s stock worth $23,001,000 after purchasing an additional 189,814 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ LNTH opened at $99.98 on Wednesday. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $104.00. The stock has a market cap of $6.51 billion, a price-to-earnings ratio of 24.09 and a beta of -0.03. The company’s 50 day moving average is $88.99 and its two-hundred day moving average is $75.77.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company’s revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LNTH. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Citizens Jmp raised their target price on Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Mizuho raised their price objective on shares of Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a report on Friday, May 1st. Finally, William Blair reiterated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.